Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BBSRC is investing £10m in 20 advanced scientific research instruments.

BBSRC is investing £10m in 20 advanced scientific research instruments under the Advanced Life Sciences Research Technology initiative (ALERT 13) to help keep the UK at the forefront of biological sciences research. Shankar Srinivas and Paul Riley from the Department of Physiology, Anatomy and Genetics, together with Ilan Davis (Biochemistry and Micron Oxford Advanced Bioimaging Unit), Jordan Raff (Sir William Dunn School of Pathology) and Roger Patient (Weatherall Institute of Molecular Medicine) have been awarded one of the UK’s first two commercial Fluorescence Light Sheet Microscopes to probe cell and tissue dynamics, worth just under £500k. This instrument will allow groups from Oxford and further afield to examine dynamic process within living cells in exquisite detail, enabling exciting advances in a broad range of areas in cell, developmental and stem cell biology.

Read more

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.